-
November 23, 2021 Manhattan Hospital Partners with Cybin to Provide Psychedelic Therapies to Marginalized Communities“It’s time for psychedelic medicine to climb down from the ivory tower and into the...
-
November 12, 2021 Psychedelic Business Spotlight: November 12This week in psychedelic business news: two of the biggest players in the industry unveil...
-
November 8, 2021 Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration...
-
November 5, 2021 Psychedelic Business Spotlight: November 5This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher...
-
November 1, 2021 Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser"Something that people used to speak about only in whispers is now standard policy," says...
-
October 29, 2021 Psychedelic Business Spotlight: October 29This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder;...
-
October 26, 2021 FDA Authorizes Cybin Device to Quantify Psychedelics’ Effects on the Brain"This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain...
-
October 22, 2021 Psychedelic Business Spotlight: October 22This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field...
-
October 15, 2021 Psychedelic Business Spotlight: October 15This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new...
-
September 24, 2021 How Cybin Is ‘Revolutionizing’ Mental Healthcare with Novel Psychedelic CompoundsCEO Doug Drysdale explains several key factors in making psychedelic-assisted therapy accessible for the millions...
